NICE Recommends BioMarin’s Vimizim® (elosulfase alfa)

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
NICE Recommends BioMarin’s Vimizim® (elosulfase alfa) for the Treatment of Morquio A Syndrome in England

SAN RAFAEL, Calif., Nov. 23, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that the The National Institute for Health and Care Excellence (NICE), NHS England and BioMarin have reached an agreement on a Managed Access Agreement, which provides a basis for access for clinically suitable mucopolysaccharidosis type IVA (MPS IVA) patients to Vimizim ® (elosulfase alfa) treatment for the next five years.  The provision of access is subject to the completion of the ongoing NICE Highly Specialised Technologies process, where the final guidance is expected in mid-December.

“The Morquio A community has been long awaiting this decision, which provides patients access to Vimizim, and we are relieved and elated to have resolution,” said Christine Lavery, Chief Executive of the MPS Society, (United Kingdom). “With fewer than 80 people living with Morquio A syndrome in England, it is hard to comprehend what these patients and their families have been through over the last 18 months. Treatment to this community is so much more than just a therapy. It is hope for a future where their improved  health allows them to reach their full potential.”

Morquio A syndrome is an ultra-rare, severely debilitating disease affecting an estimated 3,000 patients in the developed world. The most common features of the disease are progressive skeletal dysplasia, the need for frequent surgical procedures related primarily to musculoskeletal or respiratory dysfunction, and significant limitations in mobility, endurance, and breathing.

“As Vimizim is the first and only treatment to address the underlying cause of Morquio A syndrome, we applaud the Institute’s decision to provide the patient community with access to this much-needed therapy,” said Jim Lennertz, Group Vice President and Regional Manager of Europe, the Middle East and Africa at BioMarin. “As part of our commitment to the MPS community, we worked diligently with the Institute, advocates and patients to bring Vimizim to those who need it.”

The U.S. Food and Drug Administration (FDA) approved the Vimizim license application for the treatment of patients with Morquio A syndrome on February 14, 2014, and the European Commission approved it on April 28, 2014.  The therapy is also approved in Australia, Canada, Brazil and Japan.

About Vimizim Vimizim® (elosulfase alfa) is a treatment for patients with Morquio A syndrome, or mucopolysaccharidosis IVA (MPS IVA). Vimizim is the first approved enzyme replacement therapy (ERT) designed to target the underlying cause of Morquio A Syndrome—a deficiency in the enzyme N-acetylgalactosamine-6 sulfatase (GALNS). Vimizim is intended to provide the exogenous enzyme GALNS that will be taken up into the lysosomes and increase the catabolism of GAGs. Morquio A syndrome is a rare, severely debilitating and progressive disease that previously had no approved, standard-of-care treatment other than supportive care.

Important Safety Information Life-threatening allergic reactions, known as anaphylaxis, can occur during Vimizim® (elosulfase alfa) infusions. Due to the potential for anaphylaxis, appropriate medical support should be readily available when Vimizim is administered and for an appropriate period of time following administration.

Hypersensitivity reactions have been observed as early as 30 minutes from the start of infusion but as late as six days after infusion. Frequent symptoms of hypersensitivity reactions included anaphylactic reactions, urticaria, peripheral edema, cough, dyspnea, and flushing. Because of the potential for hypersensitivity reactions, administer antihistamines with or without antipyretics prior to infusion. If severe hypersensitivity reactions occur, immediately stop the infusion of Vimizim and initiate appropriate treatment. Patients with acute febrile or respiratory illness at the time of Vimizim infusion may be at higher risk of life-threatening complications from hypersensitivity reactions.

Sleep apnea is common in MPS IVA patients. Evaluation of airway patency should be considered prior to initiation of treatment with Vimizim. Patients using supplemental oxygen or continuous positive airway pressure (CPAP) during sleep should have these treatments readily available during infusion in the event of an acute reaction, or extreme drowsiness/sleep induced by antihistamine use.

Spinal or cervical cord compression (SCC) is a known and serious complication of MPS IVA and may occur as part of the natural history of the disease. In clinical trials, SCC was observed both in patients receiving Vimizim and patients receiving placebo. Patients with MPS IVA should be monitored for signs and symptoms of SCC (including back pain, paralysis of limbs below the level of compression, urinary and fecal incontinence) and given appropriate clinical care. All patients treated with Vimizim 2 mg/kg once per week in the placebo-controlled trial developed anti-drug antibodies.

Vimizim should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known if Vimizim is present in human milk.

Safety and effectiveness in pediatric patients below 5 years of age have not been established. In clinical trials, the most common adverse reactions (≥10%) occurring during infusion included pyrexia, vomiting, headache, nausea, abdominal pain, chills, and fatigue. The acute reactions requiring intervention were managed by either temporarily interrupting or discontinuing infusion, and administering additional antihistamine, antipyretics, or corticosteroids.

Please see full Prescribing Information, including boxed warning, or visit www.VIMIZIM.com .

About Morquio A Syndrome Morquio A syndrome, or Mucopolysaccharidosis IVA (MPS IVA) is a disease in which people are missing an enzyme essential in the breakdown and removal of the glycosaminoglycans (GAGs) called keratan sulfate (KS) and chondroitin-6-sulfate (C6S). The incompletely broken down GAGs remain stored in cells in the body causing progressive damage. This excessive storage causes systemic skeletal dysplasia, short stature, and joint abnormalities, limiting mobility and endurance. Malformation of the chest impairs respiratory function, and looseness of joints in the neck causing spinal instability and potentially spinal cord compression. Other symptoms may include hearing loss, corneal clouding, and heart disease. Initial symptoms often become evident in the first five years of life. The disease substantially limits both the quality and length of life of those affected. The rate of incidence of Morquio A syndrome is as yet unconfirmed and varies among different populations, and estimates vary between 1 in 200,000 live births and 1 in 450,000 live births.

About BioMarin BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.BMRN.com .

Forward-Looking Statement This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: expectations regarding NICE, NHS England and BioMarin reaching an agreement on a Managed Access Agreement for reimbursement for Vimizim.  These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: the provision of access is subject to the completion of the ongoing NICE Highly Specialised Technologies process, actual reimbursement decisions by NHS England; the acceptability of final terms of the Managed Access Agreement; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2014 Annual Report on Form 10-K, as amended, and the factors contained in BioMarin's reports on Form 8-K. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin® and Vimizim® are registered trademarks of BioMarin Pharmaceutical Inc.

Investors: Traci McCarty BioMarin Pharmaceutical Inc. (415) 455-7558 Media: Debra Charlesworth BioMarin Pharmaceutical Inc. (415) 455-7451

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bona's 2027 Floorcast Finds Wood and Trust Still Win

Updated Category News Views 47

Floors are turning into a long-game purchase again Gray flooring may be limping toward the exit, but the more important signal in Bona's 2027 Floorcast is that homeowners are thinking less like bargain hunters and more like custodians of an expensive asset. That is a useful read for anybody watching the home-improvement and maintenance landscape. People do not replace a...

Continue Reading
ASUS Brings AI Infrastructure Choices to SC26 Floor

Updated Category News Views 100

Compute buyers are sick of being handed one locked box That is the nerve ASUS is pressing at SC26: enterprises want AI infrastructure that fits the job in front of them, not somebody else's tidy product roadmap. The company is pitching a full-stack “AI Factory” blueprint built across Intel, AMD and NVIDIA hardware, running from rack-scale systems and conventional...

Continue Reading
Elah Holdings' Q3 2026 Report Sparks Investor Interest

Updated Category News Views 79

Elah Holdings Drops Their Q3 2026 Numbers Eat your heart out, folks—Elah Holdings has just dropped their third quarter report for 2026, and it caught some eyes. This ain't your run-of-the-mill, brush-right-past-it release. They're out there, waving their flag high in the competitive marketplace, trying to tell us they mean business. If you missed the announcement, they...

Continue Reading
LASIK Cost Math Deserves a Careful Second Look Today

Updated Category News Views 0

Thirty years of lens purchases can become a nasty tab Contact-lens spending has a funny way of staying invisible until somebody stacks the receipts into one ugly pile. A new cost-of-vision analysis from the surgeon advisory board of BestLASIKSurgeons.com says the average American contact-lens wearer may spend between $22,500 and $30,000 on corrective eyewear across 30...

Continue Reading
EUBG Faces Tough Third Quarter Amid Challenges

Updated Category News Views 226

What's Happening with EUBG? Entrepreneur Universe Bright Group, better known in the markets as EUBG, is navigating some choppy waters if their recent financial numbers are anything to go by. You'd think companies boasting a digital-focused strategy would be printing money in today's tech-driven world, but EUBG's third quarter of 2026 has a different story to tell. The...

Continue Reading
Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 109

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 16

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Sabre Unveils AI Travel Tech: A Bold New Frontier

Updated Category News Views 110

Sabre's Game-Changing AI Travel Integration I'm no stranger to bold moves in the travel industry, but what Sabre's rolling out tomorrow might just be the biggest leap we've seen in a while. They're unleashing what's called the first global travel plug-in within Grok Bot, marking a significant shake-up in the travel tech sphere. Too many tech upgrades in this business...

Continue Reading
RCA Mount Dora Widens Addiction Care Insurance Reach

Updated Category News Views 44

Insurance paperwork rarely looks heroic, yet it can decide whether treatment starts before a crisis gets worse. Recovery Centers of America at Mount Dora has added Aetna and Cigna/Evernorth to its in-network roster for every level of substance use disorder care, a practical move with real consequences for patients and families across Central Florida. Coverage matters most...

Continue Reading
Caracal’s $200K VMI Pledge Targets Cadet Affordability

Updated Category News Views 88

A tuition award can still leave a brutal hole in the budget. That is the plain fact sitting underneath Caracal Products & Services’ $200,000 commitment to Virginia Military Institute. Federal ROTC scholarships can cover tuition, but VMI says room, board and quartermaster fees average about $15,000 annually. For a student who has done everything right—earned the ROTC...

Continue Reading

Top 5 Most Recently Viewed Articles

T-Mobile US: A Decade of Impressive Stock Growth Revealed

Updated Category News Views 142

T-Mobile US and Its Remarkable Growth Journey T-Mobile US (NASDAQ: TMUS) has shown exceptional growth over the last decade. With an annualized return rate of 20.05%, the company has outpaced the broader market by 8.22%. As of the latest information available, T-Mobile's market capitalization stands at an impressive $269.40 billion, highlighting its substantial position...

Continue Reading
Analysts Adjust TFI International's Forecasts After Q3 Report

Updated Category News Views 67

TFI International Reports Weaker-Than-Expected Q3 Earnings After the market closed on a recent Monday, TFI International (NYSE: TFII) announced its quarterly earnings figures, which unfortunately fell below expectations. The company reported earnings of $1.60 per share, compared to analyst predictions of $1.78 per share. In addition, TFI International's quarterly revenue...

Continue Reading
C3.ai Investors Face Class Action Amidst Poor Financial Results

Updated Category News Views 179

C3.ai Class Action Overview The Portnoy Law Firm is stepping forward to represent investors of C3.ai, Inc. as a class action develops. This legal move comes after concerning preliminary financial results announced by the company. Investors who purchased securities of C3 during the specified class period are encouraged to engage with the firm. Details of the Legal Class...

Continue Reading
21st.BIO Seeks EU Nod for Precision Fermentation Tech

Updated Category News Views 172

Is Precision Fermentation Europe's Next Big Bet? Here we go again with another tech trying to revolutionize the food industry, and this time it's the Danish company 21st.BIO making strides in Europe. They've tossed their hat in the ring with an EU Novel Food application for BLG Essential+™, hoping to weave precision fermentation into the fabric of European food...

Continue Reading
Key Pfizer Executives Support Current Leadership Amid Challenges

Updated Category News Views 105

Support for Pfizer's Leadership from Former Executives In a recent statement, former Pfizer executives, Ian Read and Frank D'Amelio, clarified their stance regarding the ongoing campaign by activist investor Starboard Value. They emphasized that they will not be engaging with Starboard, which has been advocating for changes within the pharmaceutical giant to enhance its...

Continue Reading